Prophylaxis of thromboembolic events in patients with nephrotic syndrome;Profilaxis de eventos tromboembólicos en pacientes con síndrome nefrótico

Annals of Pharmacotherapy

Volumn 47, Issue 5, 2013, Pages 725-734

  Pincus, Kathleen J ^a   Hynicka, Lauren M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; DABIGATRAN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL; RIVAROXABAN; TICLOPIDINE; TINZAPARIN; WARFARIN;

ANTICOAGULATION; ARTERIAL THROMBOEMBOLISM; ARTICLE; COHORT ANALYSIS; DATA BASE; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL NORMALIZED RATIO; KIDNEY CLEARANCE; KIDNEY VEIN THROMBOSIS; LUNG EMBOLISM; MORBIDITY; MORTALITY; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 84877099424     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R530     Document Type: Article

References (60)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39:s1-s266. doi: 10.1053/ajkd.2002.30940
2. Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. BJM 2008;336: 1185-9. doi: 10.1136/bmj.39576.709711.80
3. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the national kidney foundation. Am J Kidney Dis 1999;33:1004-10. doi: 10.1016/S0272-6386%2899%2970442-7
4. Kendall AG, Lohmann RC, Dossetor JB. Nephrotic syndrome: a hypercoagulable state. Arch Intern Med 1971;127:1021-7.
5. Llach F. Hypercoagulability, renal vein thrombosis and other thrombotic complications of nephrotic syndrome. Kidney Int 1985;28:429-39.
6. Bellomo R, Atkins RC. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted? Nephron 1993;63:249-54.
7. Kauffman RH, Veltkamp JJ, Van Tilburg NH, et al. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 1978;65:607-13.
8. Panicucci F, Sagripanti A, Vispi M, et al. Comprehensive study of haemo-stasis in nephrotic syndrome. Nephron 1983;33:9-13.
9. Thompson AR. Factor XII and other hemostatic protein abnormalities in nephrotic syndrome patients. Thromb Haemost 1982;48:27-32.
10. Lange LG III, Carvalho A, Bagdasarian A, et al. Activation of Hageman factor in the nephrotic syndrome. Am J Med 1974;56:565-9.
11. Vaziri ND. Nephrotic syndrome and coagulation and fibrinolytic abnormalities. Am J Nephrol 1983;3:1-6.
12. Jackson CA, Greaves M, Patterson AD, et al. Relationship between platelet aggregation, thromboxane synthesis and albumin concentration in nephrotic syndrome. Br J Haemotol 1982;52:69-77.
13. Cosio FG, Harker C, Batard MA, et al. Plasma concentrations of the natural anticoagulants protein C and protein S in patients with proteinuria. J Lab Clin Med 1985;106:218-22.
14. Vigano-D'Angelo S, D'Angelo A, Kaufman CE Jr, et al. Protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med 1987;107:42-7.
15. Gouault-Heilmann M, Gadelha-Parente T, Levent M, et al. Total and free protein S in nephrotic syndrome. Thromb Res 1988;49:37-42.
16. Mannueci PM, Valsecc C, Bottasso B, et al. High plasma levels of protein C activity and antigen in the nephrotic syndrome. Thromb Haemost 1986;55: 31-3.
17. Kearon C, Aki E, Comerota A, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e419S-94S. doi: 10.1378/chest.11-2301
18. Barbour SH, Greenwald A, Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int 2012;81:190-5. doi: 10.1038/ki.2011.312
19. Mahmoodi BK, Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome. Circulation 2008;117:224-30. doi: 10.1161/CIRCULATIONAHA.107.716951
20. Li SJ, Guo JZ, Zuo K, et al. Thromboembolic complications in membranous nephropathy patients with nephrotic syndrome-a prospective study. Thromb Res 2012;130:501-5. doi: 10.1016/j.thromres.2012.04.015
21. Kayali F, Najjar R, Aswad F, Matta F, Stein PD. Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am J Med 2008;121:226-30. doi: 10.1016/j.amjmed.2007.08.042
22. Ruppert A, Lees M, Steinle T. Clinical burden of venous thromboembolism. Curr Med Res Opin 2010;26:2465-73. doi: 10.1185/03007995.2010.516090
23. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol 2007;18:2221-5. doi: 10.1681/ASN.2006111300
24. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:I4-8. doi: 10.1161/01.CIR.0000078468.11849.66
25. Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 2006;21:23-9. doi: 10.1007/S11239-006-5572-y
26. Rosenmann E, Pollak VE, Pirani CL. Renal vein thrombosis in the adult: a clinical and pathologic study based on renal biopsies. Medicine (Baltimore) 1968;47:269-335.
27. Kowal J, Figur A, Hitzig WM. Renal vein thrombosis and the nephrotic syndrome with complete remission. J Mt Sinai Hosp N Y 1963;30:47-58.
28. Bellomo R, Wood C, Wagner I, et al. Idiopathic membranous nephropathy in an Australian population: the incidence of thromboembolism and its impact on the natural history. Nephron 1993;63:240-1.
29. Chugh KS, Malik MD, Uberoi HS. Renal vein thrombosis in nephrotic syndrome-a prospective study and review. Postgrad Med J 1981;57:566-70.
30. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:381S-453S. doi: 10.1378/chest.08-0656
31. Wagoner RD, Stanson AW, Holley KE, Winter CS. Renal vein thrombosis in idiopathic membranous glomerulopathy and nephrotic syndrome: incidence and significance. Kidney Int 1983;23:368-74.
32. Rostoker G, Durand-Zaleski I, Petit-Phar M, et al. Prevention of thrombotic complications of the nephrotic syndrome by the low-molecularweight heparin enoxaparin. Nephron 1995;69:20-8.
33. Llach F, Papper S, Massry SG. The clinical spectrum of renal vein thrombosis: acute and chronic. Am J Med 1980;69:819-27.
34. Sarasin FP, Schifferli JA. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 1994;45:578-85.
35. Product information. Coumadin (warfarin). Princeton, NJ: Bristol Myers Squibb, October 2011.
36. Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 2010;56:823-31. doi: 10.1053/j.ajkd.2010.05.023
37. Product information. Heparin sodium injection, USP. Lake Forest, IL: Hospira, Inc., March 2008.
38. Product information. Lovenox (enoxaparin). Bridgewater, NJ: Sanofi-Aventis, April 2011.
39. Product information. Fragmin (dalteparin sodium injection). New York, NY: Pfizer, Inc., April 2007.
40. Product information. Innohep (tinzaparin sodium injection). Summit, NJ: Celgene Corporation, December 2008.
41. Product information. Pradaxa (dabigatran). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, May 2012.
42. Product information. Xarelto (rivaroxaban). Titusville, NJ: Janssen Pharmaceuticals, December 2011.
43. Product information. Arixtra (fondaprinux sodium). Research Triangle Park, NC: GlaxoSmithKline, February 2011.
44. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e24S-e43S. doi: 10.1378/chest.11-2291
45. Product information. Plavix (clopidogrel). Bridgewater, NJ: Sanofi-Aventis, December 2011.
46. Ticlopidine. Lexi-Comp Online. Hudson, OH: Lexicomp. http://online. lexi.com/lco/action/doc/retrieve/docid/patch_f/7769 (accessed 2012 Jul 27).
47. Kato Y, Kobayashi H, Mihara H, et al. Ticlopidine treatment in idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia accompanied by nephrotic syndrome. Intern Med 1992;31:504-7. doi: 10.2169/internalmedicine.31.504
48. Product information. Effient (prasugrel). Indianapolis, IN: Eli Lilly and Co, September 2011.
49. Tholl U, Anlauf M, Helmchen U. Clopidogrel and membranous nephropathy. Lancet 1999;354:1443-4. doi: 10.1016/S0140-6739(99)02586-6
50. Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 2010;56:823-31. doi: 10.1053/j.ajkd.2010.05.023
51. Ganeval D, Fischer AM, Barre J, et al. Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. Clin Nephrol 1986;25:75-80.
52. Kleinow ME, Garwood CL, Clemente JL, Whittaker P. Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic. J Manag Care Pharm 2011;17:523-30.
53. Agarwal V, Phung OJ, Tongbram V, et al. Statin use and the prevention of venous thromboembolism: a meta-analysis. Int J Clin Pract 2010;64: 1375-83. doi: 10.1111/j.1742-1241.2010.02439.x
54. Evans NS, Green D. ASH evidence-based guidelines: statins in the prevention of venous thromboembolism. Hematology Am Soc Hematol Educ Program 2009:273-4. doi: 10.1182/asheducaition-2009.1.273
55. Khemasuwan D, Chae YK, Gupta S, et al. Dose-related effect of statins in venous thrombosis risk reduction. Am J Med 2011;124:852-9. doi: 10.1016/j.amjmed.2011.04.019
56. Pai M, Evans NS, Shah SJ, et al. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. Thromb Res 2011;128:422-30. doi: 10.1016/j.thromres.2011.05.012
57. Resh M, Mahmoodi RK, Navis CJ, et al. Statin use in patients with nephrotic syndrome is associated with a lower risk of venous thromboembolism. Thromb Res 2011;127:395-9. doi: 10.1016/j.thromres.2010.12.020
58. McByrde KD, Kershaw DB, Smoyer WE. Pediatric steroid-resistant nephrotic syndrome. Curr Probl Pediatr Adolesc Health Care 2001;31: 275-307. doi: 10.1067/mps.2001.119800
59. Hodson EM. The management of idiopathic nephrotic syndrome in children. Pediatr Drugs 2003;5:335-49.
60. Akoglu H, Agbahi K, Piskinpasa S, et al. High frequency of aspirin resistance in patients with nephrotic syndrome. Nephrol Dial Transplant 2012;27:1460-6. doi: 10.1093/ndt/gfr476